{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-25-000114","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.463569+00:00","generated_at":"2026-05-17T14:35:17.616394+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elicio publishes Phase 1 ELI-002 data in Nature Medicine: OS 28.94 months, 77% risk reduction","bullets":["At 19.7 mo median follow-up, median OS increased to 28.94 months from 16.33 months in Phase 1 AMPLIFY-201.","Above-threshold T cell responses gave 77% reduction in death risk (HR 0.23) and 88% reduction in relapse risk (HR 0.12).","84% (21/25) of patients had tumor biomarker responses; 24% (6/25) achieved complete biomarker clearance.","Final event-driven DFS analysis for Phase 2 AMPLIFY-7P study of ELI-002 7P in PDAC anticipated Q4 2025.","ELI-002 was well tolerated; no dose-limiting toxicities or ≥Grade 3 treatment-related adverse events observed."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-25-000114","json":"https://secwatch.observer/filing/0001601485-25-000114.json","markdown":"https://secwatch.observer/filing/0001601485-25-000114.md","text":"https://secwatch.observer/filing/0001601485-25-000114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148525000114/0001601485-25-000114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148525000114/angn-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:35:17.616394+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}